

Yingjie Zhang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/535309/yingjie-zhang-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86

papers

1,372

citations

20

h-index

33

g-index

95

ext. papers

1,697

ext. citations

4.7

avg, IF

4.67

L-index

#	Paper	IF	Citations
86	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022 , 128797	2.9	
85	Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.. <i>ACS Medicinal Chemistry Letters</i> , 2021 , 12, 1932-1941	4.3	
84	Correlation Between Lung Density Changes Under Different Dose Gradients and Radiation Pneumonitis-Based on an Analysis of Computed Tomography Scans During Esophageal Cancer Radiotherapy. <i>Frontiers in Oncology</i> , 2021 , 11, 650764	5.3	1
83	A comparison of the location in membranes of curcumin and curcumin-derived bivalent compounds with potential neuroprotective capacity for Alzheimer's disease. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021 , 199, 111525	6	4
82	Discovery of Novel Pyrrolo[2,3-]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	13
81	Comparison of the Gross Target Volumes Based on Diagnostic PET/CT for Primary Esophageal Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 550100	5.3	1
80	Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. <i>Investigational New Drugs</i> , 2021 , 1	4.3	0
79	Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. <i>Bioorganic Chemistry</i> , 2021 , 116, 105343	5.1	
78	Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. <i>Bioorganic Chemistry</i> , 2021 , 116, 105278	5.1	3
77	Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis.. <i>RSC Advances</i> , 2021 , 11, 21426-21432	3.7	1
76	Potent Hydrazone-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	3
75	In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875. <i>Drug Development Research</i> , 2020 , 81, 708-715	5.1	1
74	Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 995	5.3	8
73	Letter to the editor: Is it reasonable to prescribe RAI for all DTC patients with a primary tumor diameter exceeding 1cm?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2505-2506	8.8	8
72	Design of Hydrazone-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 5501-5525	8.3	15
71	Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020 , 30, 263-274	6.8	34
70	Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. <i>Bioorganic Chemistry</i> , 2020 , 104, 104235	5.1	0

69	Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 454	5.7	4
68	Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. <i>Molecules</i> , 2020 , 25,	4.8	6
67	Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 978-990	3.4	5
66	Setup Error Assessment and Correction in Planar kV Image- Versus Cone Beam CT Image-Guided Radiation Therapy: A Clinical Study of Early Breast Cancer Treated With External Beam Partial Breast Irradiation. <i>Technology in Cancer Research and Treatment</i> , 2019 , 18, 1533033819853847	2.7	2
65	Role of thyroglobulin in the management of patients with differentiated thyroid cancer. <i>Clinical and Translational Imaging</i> , 2019 , 7, 209-217	2	1
64	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3898-3923	8.3	38
63	Importin-4 functions as a driving force in human primary gastric cancer. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 12638-12646	4.7	2
62	A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. <i>Journal of Neuroinflammation</i> , 2019 , 16, 81	10.1	76
61	Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. <i>Molecules</i> , 2019 , 24,	4.8	16
60	Postmastectomy radiotherapy using three different techniques: a retrospective evaluation of the incidental dose distribution in the internal mammary nodes. <i>Cancer Management and Research</i> , 2019 , 11, 1097-1106	3.6	2
59	Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer. <i>Cancer Letters</i> , 2019 , 443, 1-12	9.9	18
58	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018 , 150, 282-291	6.8	15
57	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 2589-2603	8.3	38
56	Design, Synthesis, and Biological Evaluation of Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors. <i>ChemMedChem</i> , 2018 , 13, 431-436	3.7	8
55	JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. <i>Current Drug Targets</i> , 2018 , 19, 487-500	3	31
54	Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 3145-3157	3.4	7
53	Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 1241-1251	2.2	9
52	Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2018 , 143, 334-347	6.8	11

51	External-beam partial breast irradiation in a supine versus prone position after breast-conserving surgery for Chinese breast cancer patients. <i>Scientific Reports</i> , 2018 , 8, 15354	4.9	6
50	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 5304-5322	8.3	57
49	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. <i>European Journal of Medicinal Chemistry</i> , 2017 , 134, 185-206	6.8	20
48	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 2981-2994	3.4	19
47	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 2666-2675	3.4	14
46	Discovery of a fluorescent probe with HDAC6 selective inhibition. <i>European Journal of Medicinal Chemistry</i> , 2017 , 141, 596-602	6.8	16
45	Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 535-541	4.4	3
44	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 4614-4619	3.4	2
43	Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017 , 17, 802-812	2.2	24
42	Comparison of biological target volume metrics based on FDG PET-CT and 4DCT for primary non-small-cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 79629-79635	3.3	
41	Nitric oxide donor hybrid compounds as promising anticancer agents. <i>Drug Discoveries and Therapeutics</i> , 2017 , 10, 276-284	5	15
40	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1)-pyrazole Derivatives as JAKs Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016 , 7, 950-955	4.3	21
39	Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents. <i>Chemical Biology and Drug Design</i> , 2016 , 88, 542-55	2.9	4
38	Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. <i>European Journal of Medicinal Chemistry</i> , 2016 , 121, 649-657	6.8	18
37	Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. <i>European Journal of Medicinal Chemistry</i> , 2016 , 108, 21-27	6.8	9
36	Comparison of planning target volumes based on three-dimensional and four-dimensional CT imaging of thoracic esophageal cancer. <i>OncoTargets and Therapy</i> , 2016 , 9, 4785-91	4.4	1
35	Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU. <i>Medicinal Chemistry</i> , 2016 , 12, 30-6	1.8	5
34	PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors. <i>Chemical Biology and Drug Design</i> , 2016 , 88, 574-84	2.9	3

33	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 2660-72	3.4	6
32	Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5787-5795	3.4	10
31	Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 5539-45	3.4	4
30	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 4481-4488	3.4	17
29	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 4325-38	8.3	61
28	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 6632-40	3.4	4
27	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 6258-70	3.4	11
26	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. <i>European Journal of Medicinal Chemistry</i> , 2015 , 89, 628-37	6.8	12
25	Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 5553-67	4.4	3
24	Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. <i>Drug Discoveries and Therapeutics</i> , 2015 , 9, 147-55	5	6
23	Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse. <i>Drug Discoveries and Therapeutics</i> , 2015 , 9, 45-52	5	11
22	Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 1487-95	3.4	14
21	Design, synthesis and preliminary evaluation of β -sulfonyl α -(glycinyloxy)proline peptidomimetics as matrix metalloproteinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 3055-64	3.4	15
20	3D QSAR and docking studies of a series of histone deacetylase inhibitors. <i>Medicinal Chemistry Research</i> , 2014 , 23, 2229-2241	2.2	3
19	Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 8445-58	8.3	50
18	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 3324-41	8.3	56
17	Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. <i>Anti-Cancer Drugs</i> , 2014 , 25, 767-77	2.4	3
16	VEGF signal system: the application of antiangiogenesis. <i>Current Medicinal Chemistry</i> , 2014 , 21, 894-910	4.3	35

15	Progress of HDAC inhibitor panobinostat in the treatment of cancer. <i>Current Drug Targets</i> , 2014 , 15, 622-34	3	26
14	Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. <i>Chemical Biology and Drug Design</i> , 2013 , 82, 125-30	2.9	5
13	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II. <i>European Journal of Medicinal Chemistry</i> , 2013 , 69, 191-200	6.8	9
12	Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study. <i>RSC Advances</i> , 2013 , 3,	3.7	2
11	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptanaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth. <i>European Journal of Medicinal Chemistry</i> , 2013 , 64, 377-88	6.8	23
10	Development of -Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group. <i>ACS Medicinal Chemistry Letters</i> , 2013 , 4, 235-238	4.3	38
9	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 5532-9	8.3	48
8	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 2823-38	8.3	75
7	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 5387-97	6.8	19
6	Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 4437-44	3.4	15
5	Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in peptides and peptidomimetics design and discovery. <i>Current Protein and Peptide Science</i> , 2010 , 11, 752-8	2.8	5
4	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 1761-72	3.4	53
3	The structure and function of histone deacetylases: the target for anti-cancer therapy. <i>Current Medicinal Chemistry</i> , 2008 , 15, 2840-9	4.3	49
2	Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008 , 8, 698-704	2.2	44
1	Progress on kinesin spindle protein inhibitors as anti-cancer agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008 , 8, 698-704	2.2	17